SAN DIEGO, CA – Illumina Inc, headquartered in San Diego, California, announced the opening of a new office and state-of-the-art Solutions Center in Bengaluru, India.
The expansion comes after 16 years of close collaboration with channel partner, Premas Life Sciences. Now with its own permanent facility, the California-based company will continue to collaborate with Premas to grow the genomics market in India, recognized by the United Nations as the world’s most populous country with more than 1.4 billion people.
“Expanding Illumina’s presence in India allows the company to collaborate and be part of a vibrant biotech ecosystem with a skilled workforce, strong research and development resources and supportive government policies,” said Gretchen Weightman, senior vice president, Asia Pacific, Middle East and Africa.
Illumina has supported TB surveillance for the past seven years in India through the FIND Seq&Treat project, which aims to increase the adoption of next-generation sequencing (NGS) for affordable, scalable and rapid TB drug susceptibility testing.
In addition, the company has undertaken initiatives to increase access to sequencing capacity in India; this includes philanthropic funding with the Bill and Melinda Gates Foundation and the Rockefeller Foundation to support COVID-19 surveillance.
Illumina currently employs more than 30 people in India in sales, operations, marketing, government relations and human resources, with more hires expected as the company expands its operations in the country.
The new Solutions Center features a fully equipped laboratory housing the latest NGS technologies and is fully resourced with field applications and service engineers to provide partners and customers with extensive genomic capabilities.
No related posts.
